Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02YIW
|
||||
| Former ID |
DIB018634
|
||||
| Drug Name |
5-(N,N-hexamethylene)-amiloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H18ClN7O
|
||||
| InChI |
InChI=1S/C12H18ClN7O/c13-8-10(20-5-3-1-2-4-6-20)18-9(14)7(17-8)11(21)19-12(15)16/h1-6H2,(H2,14,18)(H4,15,16,19,21)
|
||||
| InChIKey |
RQQJJXVETXFINY-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
3721421, 5244802, 8151288, 11110798, 11342050, 11362233, 11364490, 11367052, 11369614, 11372762, 11374345, 11377776, 11485593, 11487635, 11489485, 11491477, 11492438, 11495410, 14776630, 17404667, 24278246, 26612673, 26680153, 26749339, 29220993, 47291316, 47500609, 47736700, 48110661, 48334713, 50064415, 50105831, 50105832, 50107574, 53777210, 56463449, 57321027, 71822511, 79418853, 85086636, 85230925, 85788510, 90340799, 92303675, 93166515, 103128691, 103615298, 104298740, 117465724, 121360894
|
||||
| Target and Pathway | |||||
| Target(s) | Gonadotropin-releasing hormone receptor | Target Info | Modulator (allosteric modulator) | [2] | |
| Alpha-2C adrenergic receptor | Target Info | Modulator (allosteric modulator) | [3] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| GnRH signaling pathwayhsa04022:cGMP-PKG signaling pathway | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Hormone ligand-binding receptors | ||||
| G alpha (q) signalling eventsR-HSA-390696:Adrenoceptors | |||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP58:Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1192). | ||||
| REF 2 | Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol Pharmacol. 2008 Jun;73(6):1808-15. | ||||
| REF 3 | Characterization of the allosteric interactions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor. Mol Pharmacol. 1998 May;53(5):916-25. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.